Osteoporosis

March 4th 2025

The new approval expands the portfolio of denosumab biosimilars, increasing access and improving costs for patients.

February 17th 2025

The approval in multiple indications is designed to improve access to effective, proven treatments for skeletal fractures, which can greatly reduce patient quality of life.

January 29th 2025

Through similar targeting of the RdRp enzyme, these treatments could offer groundbreaking new options for patients with COVID-19 if proven effective in real-world trials.

December 2nd 2024

Investigators presented additional data from a clinical trial at the American College of Rheumatology Convergence, demonstrating similar safety for postmenopausal women with osteoporosis.